237 related articles for article (PubMed ID: 28594000)
1. Synthesis and preliminary PET imaging of
Collier TL; Normandin MD; Stephenson NA; Livni E; Liang SH; Wooten DW; Esfahani SA; Stabin MG; Mahmood U; Chen J; Wang W; Maresca K; Waterhouse RN; El Fakhri G; Richardson P; Vasdev N
Nat Commun; 2017 Jun; 8():15761. PubMed ID: 28594000
[TBL] [Abstract][Full Text] [Related]
2. Brain Penetration of the ROS1/ALK Inhibitor Lorlatinib Confirmed by PET.
Collier TL; Maresca KP; Normandin MD; Richardson P; McCarthy TJ; Liang SH; Waterhouse RN; Vasdev N
Mol Imaging; 2017; 16():1536012117736669. PubMed ID: 29067878
[TBL] [Abstract][Full Text] [Related]
3. First macrocyclic 3
Basit S; Ashraf Z; Lee K; Latif M
Eur J Med Chem; 2017 Jul; 134():348-356. PubMed ID: 28431340
[TBL] [Abstract][Full Text] [Related]
4. P-glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450-3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib.
Li W; Sparidans RW; Wang Y; Lebre MC; Wagenaar E; Beijnen JH; Schinkel AH
Int J Cancer; 2018 Oct; 143(8):2029-2038. PubMed ID: 29744867
[TBL] [Abstract][Full Text] [Related]
5. Lorlatinib: First Global Approval.
Syed YY
Drugs; 2019 Jan; 79(1):93-98. PubMed ID: 30604291
[TBL] [Abstract][Full Text] [Related]
6. Oral coadministration of elacridar and ritonavir enhances brain accumulation and oral availability of the novel ALK/ROS1 inhibitor lorlatinib.
Li W; Sparidans RW; Wang Y; Lebre MC; Beijnen JH; Schinkel AH
Eur J Pharm Biopharm; 2019 Mar; 136():120-130. PubMed ID: 30660696
[TBL] [Abstract][Full Text] [Related]
7. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Shaw AT; Felip E; Bauer TM; Besse B; Navarro A; Postel-Vinay S; Gainor JF; Johnson M; Dietrich J; James LP; Clancy JS; Chen J; Martini JF; Abbattista A; Solomon BJ
Lancet Oncol; 2017 Dec; 18(12):1590-1599. PubMed ID: 29074098
[TBL] [Abstract][Full Text] [Related]
8. Lorlatinib for the treatment of patients with non-small cell lung cancer.
Akamine T; Toyokawa G; Tagawa T; Yamazaki K; Seto T; Takeo S; Mori M
Drugs Today (Barc); 2019 Feb; 55(2):107-116. PubMed ID: 30816885
[TBL] [Abstract][Full Text] [Related]
9. Investigation on the binding mechanism of loratinib with the c-ros oncogene 1 (ROS1) receptor tyrosine kinase via molecular dynamics simulation and binding free energy calculations.
Wu X; Wang Y; Wan S; Zhang J
J Biomol Struct Dyn; 2018 Sep; 36(12):3106-3113. PubMed ID: 28893136
[TBL] [Abstract][Full Text] [Related]
10. Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations.
Johnson TW; Richardson PF; Bailey S; Brooun A; Burke BJ; Collins MR; Cui JJ; Deal JG; Deng YL; Dinh D; Engstrom LD; He M; Hoffman J; Hoffman RL; Huang Q; Kania RS; Kath JC; Lam H; Lam JL; Le PT; Lingardo L; Liu W; McTigue M; Palmer CL; Sach NW; Smeal T; Smith GL; Stewart AE; Timofeevski S; Zhu H; Zhu J; Zou HY; Edwards MP
J Med Chem; 2014 Jun; 57(11):4720-44. PubMed ID: 24819116
[TBL] [Abstract][Full Text] [Related]
11. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.
Zou HY; Li Q; Engstrom LD; West M; Appleman V; Wong KA; McTigue M; Deng YL; Liu W; Brooun A; Timofeevski S; McDonnell SR; Jiang P; Falk MD; Lappin PB; Affolter T; Nichols T; Hu W; Lam J; Johnson TW; Smeal T; Charest A; Fantin VR
Proc Natl Acad Sci U S A; 2015 Mar; 112(11):3493-8. PubMed ID: 25733882
[TBL] [Abstract][Full Text] [Related]
12. Translational pharmacokinetic-pharmacodynamic modeling for an orally available novel inhibitor of anaplastic lymphoma kinase and c-Ros oncogene 1.
Yamazaki S; Lam JL; Zou HY; Wang H; Smeal T; Vicini P
J Pharmacol Exp Ther; 2014 Oct; 351(1):67-76. PubMed ID: 25073473
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetic model with time-varying clearance for lorlatinib using pooled data from patients with non-small cell lung cancer and healthy participants.
Chen J; Houk B; Pithavala YK; Ruiz-Garcia A
CPT Pharmacometrics Syst Pharmacol; 2021 Feb; 10(2):148-160. PubMed ID: 33449423
[TBL] [Abstract][Full Text] [Related]
14. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
Facchinetti F; Loriot Y; Kuo MS; Mahjoubi L; Lacroix L; Planchard D; Besse B; Farace F; Auger N; Remon J; Scoazec JY; André F; Soria JC; Friboulet L
Clin Cancer Res; 2016 Dec; 22(24):5983-5991. PubMed ID: 27401242
[TBL] [Abstract][Full Text] [Related]
15. A Facile Radiolabeling of [
Wang L; Cheng R; Fujinaga M; Yang J; Zhang Y; Hatori A; Kumata K; Yang J; Vasdev N; Du Y; Ran C; Zhang MR; Liang SH
J Med Chem; 2017 Jun; 60(12):5222-5227. PubMed ID: 28530834
[TBL] [Abstract][Full Text] [Related]
16. A user's guide to lorlatinib.
Nagasaka M; Ge Y; Sukari A; Kukreja G; Ou SI
Crit Rev Oncol Hematol; 2020 Jul; 151():102969. PubMed ID: 32416346
[TBL] [Abstract][Full Text] [Related]
17. ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers.
Roskoski R
Pharmacol Res; 2017 Jul; 121():202-212. PubMed ID: 28465216
[TBL] [Abstract][Full Text] [Related]
18. Conformational Studies and Atropisomerism Kinetics of the ALK Clinical Candidate Lorlatinib (PF-06463922) and Desmethyl Congeners.
Elleraas J; Ewanicki J; Johnson TW; Sach NW; Collins MR; Richardson PF
Angew Chem Int Ed Engl; 2016 Mar; 55(11):3590-5. PubMed ID: 26880581
[TBL] [Abstract][Full Text] [Related]
19. [
Kumata K; Zhang Y; Fujinaga M; Ohkubo T; Mori W; Yamasaki T; Hanyu M; Xie L; Hatori A; Zhang MR
Bioorg Med Chem; 2018 Sep; 26(17):4817-4822. PubMed ID: 30166255
[TBL] [Abstract][Full Text] [Related]
20. Fully automated synthesis of PET TSPO radioligands [11C]DAA1106 and [18F]FEDAA1106.
Wang M; Gao M; Zheng QH
Appl Radiat Isot; 2012 Jun; 70(6):965-73. PubMed ID: 22469868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
